CO2023009994A2 - Mutaciones en regiones constantes de anticuerpos caninos - Google Patents
Mutaciones en regiones constantes de anticuerpos caninosInfo
- Publication number
- CO2023009994A2 CO2023009994A2 CONC2023/0009994A CO2023009994A CO2023009994A2 CO 2023009994 A2 CO2023009994 A2 CO 2023009994A2 CO 2023009994 A CO2023009994 A CO 2023009994A CO 2023009994 A2 CO2023009994 A2 CO 2023009994A2
- Authority
- CO
- Colombia
- Prior art keywords
- mutations
- constant regions
- canine antibodies
- canine
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163142774P | 2021-01-28 | 2021-01-28 | |
| PCT/US2022/014146 WO2022165067A2 (en) | 2021-01-28 | 2022-01-27 | Mutations in canine antibody constant regions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023009994A2 true CO2023009994A2 (es) | 2023-08-09 |
Family
ID=80786846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0009994A CO2023009994A2 (es) | 2021-01-28 | 2023-07-27 | Mutaciones en regiones constantes de anticuerpos caninos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240059777A1 (https=) |
| EP (2) | EP4284825A2 (https=) |
| JP (1) | JP2024505072A (https=) |
| KR (1) | KR20230136604A (https=) |
| CN (1) | CN116802205A (https=) |
| AU (1) | AU2022214843A1 (https=) |
| CA (1) | CA3207285A1 (https=) |
| CL (2) | CL2023002202A1 (https=) |
| CO (1) | CO2023009994A2 (https=) |
| EC (1) | ECSP23057156A (https=) |
| IL (1) | IL304522A (https=) |
| MX (1) | MX2023008785A (https=) |
| PE (1) | PE20231919A1 (https=) |
| TW (1) | TW202246318A (https=) |
| WO (1) | WO2022165067A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| EP4284825A2 (en) | 2021-01-28 | 2023-12-06 | Zoetis Services LLC | Mutations in canine antibody constant regions |
| JP2025529206A (ja) * | 2022-09-02 | 2025-09-04 | ゾエティス・サービシーズ・エルエルシー | 豚抗体変異体 |
| CN121574951B (zh) * | 2026-01-27 | 2026-04-28 | 金发科技股份有限公司 | 一种苹果酸脱氢酶、含有其的工程化库德里亚兹毕赤酵母及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20200181258A1 (en) * | 2016-10-17 | 2020-06-11 | Vetoquinol Sa | Modified antibody constant region |
| US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
| CN113544153B (zh) * | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| EP4284825A2 (en) | 2021-01-28 | 2023-12-06 | Zoetis Services LLC | Mutations in canine antibody constant regions |
-
2022
- 2022-01-27 EP EP22704666.1A patent/EP4284825A2/en active Pending
- 2022-01-27 WO PCT/US2022/014146 patent/WO2022165067A2/en not_active Ceased
- 2022-01-27 JP JP2023545996A patent/JP2024505072A/ja active Pending
- 2022-01-27 CA CA3207285A patent/CA3207285A1/en active Pending
- 2022-01-27 PE PE2023002227A patent/PE20231919A1/es unknown
- 2022-01-27 MX MX2023008785A patent/MX2023008785A/es unknown
- 2022-01-27 US US18/270,062 patent/US20240059777A1/en active Pending
- 2022-01-27 CN CN202280010912.XA patent/CN116802205A/zh active Pending
- 2022-01-27 AU AU2022214843A patent/AU2022214843A1/en active Pending
- 2022-01-27 KR KR1020237025434A patent/KR20230136604A/ko active Pending
- 2022-01-27 EP EP24210430.5A patent/EP4512416A3/en active Pending
- 2022-01-28 TW TW111104187A patent/TW202246318A/zh unknown
-
2023
- 2023-07-17 IL IL304522A patent/IL304522A/en unknown
- 2023-07-26 CL CL2023002202A patent/CL2023002202A1/es unknown
- 2023-07-27 CO CONC2023/0009994A patent/CO2023009994A2/es unknown
- 2023-07-27 EC ECSENADI202357156A patent/ECSP23057156A/es unknown
-
2024
- 2024-05-24 CL CL2024001562A patent/CL2024001562A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022165067A2 (en) | 2022-08-04 |
| MX2023008785A (es) | 2023-12-14 |
| TW202246318A (zh) | 2022-12-01 |
| ECSP23057156A (es) | 2023-08-31 |
| CA3207285A1 (en) | 2022-08-04 |
| IL304522A (en) | 2023-09-01 |
| EP4512416A2 (en) | 2025-02-26 |
| US20240059777A1 (en) | 2024-02-22 |
| JP2024505072A (ja) | 2024-02-02 |
| CL2024001562A1 (es) | 2024-08-23 |
| EP4512416A3 (en) | 2025-06-18 |
| AU2022214843A1 (en) | 2023-07-20 |
| KR20230136604A (ko) | 2023-09-26 |
| EP4284825A2 (en) | 2023-12-06 |
| PE20231919A1 (es) | 2023-11-28 |
| WO2022165067A3 (en) | 2022-09-22 |
| CL2023002202A1 (es) | 2024-01-12 |
| AU2022214843A9 (en) | 2024-05-16 |
| CN116802205A (zh) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001562A1 (es) | Mutaciones en regiones constantes de anticuerpos caninos. | |
| CL2023003377A1 (es) | Variantes de anticuerpos caninos | |
| CL2023003376A1 (es) | Variantes de anticuerpos felinos | |
| CL2024001519A1 (es) | Mutaciones en regiones constantes de anticuerpos felinos. | |
| ECSP23030271A (es) | Variantes de anticuerpos caninos | |
| CO2023007146A2 (es) | Variantes de anticuerpos bovinos | |
| CL2023000895A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
| CO2019001111A2 (es) | Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos | |
| TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
| EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
| CL2024000789A1 (es) | Variantes de anticuerpos felinos. | |
| SA523450918B1 (ar) | أجسام مضادة للنكتين-4 واستخداماتها | |
| EA201992776A1 (ru) | Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях | |
| CO2024007674A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| MX2025002524A (es) | Mutantes de anticuerpos equinos | |
| EA202192532A1 (ru) | Мирикизумаб для применения в способе лечения болезни крона | |
| EA201991614A1 (ru) | СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ | |
| TWD200747S (zh) | 髮夾 | |
| TWD191507S (zh) | Spine adjustment loose band |